scholarly journals Juvenile Idiopathic Arthritis in Jordan: Single-Center Experience

2020 ◽  
Author(s):  
Raed Alzyoud ◽  
Motasem O. Alsuweiti ◽  
Heba Q. Almaaitah ◽  
Bushra N. Aladaileh ◽  
Mohammad K. Alnoubani ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Age At Onset ◽  
Laboratory Data ◽  
Population Based ◽  
Single Center ◽  
Rheumatology Clinic ◽  
Single Center Experience ◽  
Single Center Study ◽  
Pediatric Rheumatology Clinic ◽  
International League

Abstract Background: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders, including all forms of arthritis, begin in children who are less than 16 years old. This study aims to evaluate the clinical and laboratory features of JIA in Jordanian children in a single center.Methods: A retrospective analysis of the medical records of pediatric patients who were diagnosed as JIA based on the International League of Associations for Rheumatology (ILAR) criteria from 2015 through 2019 at a pediatric Rheumatology clinic in Queen Rania Children Hospital. All patients were below the age of 14 at the time of diagnosis. Collected data included age, gender, age at initial presentation and diagnosis, JIA subtypes, and laboratory data.Results: A total of 210 patients were included in this cohort (94 males and 116 females) with a mean age at diagnosis 5.33 ± 3.4 years and the mean age at onset of the disease was 5.08 ± 3.4 years (range 7 months – 14 years). Oligoarticular JIA was the commonest subtype (54.7%), followed by systemic arthritis (17.1%), polyarticular (12.3%). ANA was positive in 70 patients (33.6%). Uveitis occurred in thirty (14.2%) patientsConclusion: To the best of our knowledge, this cohort is the first report on JIA in Jordan, in comparison with other regional and international published reports, Oligoarticular JIA found to be the most common Subtype in our experience. To have more details about JIA characteristics, a population-based rather than a single-center study needs to be conducted in Jordan

scholarly journals Juvenile idiopathic arthritis in Jordan: Single center experience

2021 ◽  
Author(s):  
Raed M. Alzyoud ◽  
Motasem O. Alsuweiti ◽  
Heba Q. Almaaitah ◽  
Bushra N. Aladaileh ◽  
Mohammad K. Alnoubani ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Treatment Options ◽  
Age At Onset ◽  
Laboratory Data ◽  
Population Based ◽  
Detailed Knowledge ◽  
Single Center ◽  
Rheumatology Clinic ◽  
Single Center Experience ◽  
Single Center Study

Abstract Background: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders, including all forms of arthritis, which develops in children who are less than 16 years old. This study aimed to evaluate the clinical and laboratory features of JIA in a single center in Jordan.Methods: A retrospective analysis of the electronic medical records of pediatric patients diagnosed with JIA based on the International League of Associations for Rheumatology (ILAR) criteria during the period from 2015 to 2019 at the Pediatric Rheumatology Clinic in the Queen Rania Children’s Hospital. All patients were below the age of 14 years at the time of diagnosis and followed for at least six months. Collected data consisted of age, gender, age at initial presentation and diagnosis, JIA subtype, laboratory data, treatment options, and outcome.Results: A total of 210 patients were included in this cohort (94 males and 116 females) with the mean age at diagnosis and mean age at onset of 5.33 ± 3.40 years and 5.08 ± 3.40 years (range: 7 months – 14 years), respectively. Oligoarticular JIA was the commonest subtype (54.7%), followed by systemic arthritis (17.1%) and polyarticular arthritis (12.3%). ANA was positive in 70 patients (33.6%). Uveitis occurred in thirty (14.2%) patients.Conclusion: To the best of our knowledge, this study on this cohort is the first report on JIA in Jordan, in comparison with other regionally and internationally published reports. Oligoarticular JIA was found to be the most common subtype. For detailed knowledge on JIA characteristics and patterns, a population-based, rather than a single center study, should be conducted in Jordan.

scholarly journals Juvenile idiopathic arthritis in Jordan: single center experience

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Raed M. Alzyoud ◽  
Motasem O. Alsuweiti ◽  
Heba Q. Almaaitah ◽  
Bushra N. Aladaileh ◽  
Mohammad K. Alnoubani ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Treatment Options ◽  
Age At Onset ◽  
Laboratory Data ◽  
Population Based ◽  
Detailed Knowledge ◽  
Single Center ◽  
Rheumatology Clinic ◽  
Single Center Experience ◽  
Single Center Study

Abstract Background Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders, including all forms of arthritis, which develops in children who are less than 16 years old. This study aimed to evaluate the clinical and laboratory features of JIA in a single center in Jordan. Methods A retrospective analysis of the electronic medical records of Pediatric patients diagnosed with JIA based on the International League of Associations for Rheumatology (ILAR) criteria during the period from 2015 to 2019 at the Pediatric Rheumatology Clinic in the Queen Rania Children’s Hospital. All patients were below the age of 14 years at the time of diagnosis and followed for at least 6 months. Collected data consisted of age, gender, age at initial presentation and diagnosis, JIA subtype, laboratory data, treatment options, and outcome. Results A total of 210 patients were included in this cohort (94 males and 116 females) with the mean age at diagnosis and mean age at onset of 5.33 ± 3.40 years and 5.08 ± 3.40 years (range: 7 months – 14 years), respectively. Oligoarticular JIA was the commonest subtype (54.7%), followed by systemic arthritis (17.1%) and polyarticular arthritis (12.3%). ANA was positive in 70 patients (33.6%). Uveitis occurred in 30 (14.2%) patients. Conclusion To the best of our knowledge, this study on this cohort is the first report on JIA in Jordan, in comparison with other regionally and internationally published reports. Oligoarticular JIA was found to be the most common subtype. For detailed knowledge on JIA characteristics and patterns, a population-based, rather than a single center study, should be conducted in Jordan.

scholarly journals The Pattern of Juvenile Idiopathic Arthritis in a Single Tertiary Center in Saudi Arabia

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Mohammad H. Al-Hemairi ◽  
Shatha M. Albokhari ◽  
Mohammed A. Muzaffer
Keyword(s):  
Saudi Arabia ◽  
Juvenile Idiopathic Arthritis ◽  
Population Based ◽  
Chronic Arthritis ◽  
Rheumatology Clinic ◽  
Single Center Study ◽  
Tertiary Center ◽  
Systemic Onset ◽  
Pediatric Rheumatology Clinic

Introduction.Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis in children. Our aim is to describe demographic, clinical, and laboratory characteristics and treatment of JIA patients followed up in Pediatric Rheumatology clinic in a tertiary center in Saudi Arabia.Methods. Medical records of all patients who are followed up between January 2007 and January 2015 were retrospectively reviewed. Data were collected about demographic, clinical, and laboratory features and treatment.Results.Total patients were 82, males were 31 (37.8%), and mean age of JIA onset was 7.1 ± 3.6 yr. Mean follow-up duration was 2.67±1.6 yr. Systemic onset JIA (SoJIA) was the commonest (36.5%), followed by polyarticular in 29.2% and oligoarticular in 28%. Large and small joints are involved in 76 (92%) and 30 (36.6%), respectively. Main extra-articular feature was fever in 34 (41.4%). Uveitis was diagnosed in 7 (8.5%) and in 5 (21.7%) of oligoarticular JIA. Anemia was found in 49 (59.7%), high ESR in 45 (54.8%), and leukocytosis and thrombocytosis in 33 (40.2%). Positive ANA was found in 30 (36.5%) mainly in oligoarticular subtype as 12 (52%) patients (out of 23) had this positive test. 9 patients (10.9%) required NSAIDs only, 6 patients (7.3%) required NSAIDs and intra-articular steroids only, and 19 (23%) required NSAIDs, methotrexate, steroids, and biologics.Conclusion.SoJIA is the most common JIA subtype in our study. A population based rather than a single center study will give more details about JIA characteristics in Saudi Arabia

scholarly journals Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome Resembling Juvenile Idiopathic Arthritis: A Single-Center Experience from Southern Turkey

2021 ◽  
pp. 1-6
Author(s):  
Rabia Miray Kisla Ekinci ◽  
Sibel Balci ◽  
Haldun Dogan ◽  
Serdar Ceylaner ◽  
Celal Varan ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Pericardial Effusion ◽  
Early Onset ◽  
Joint Space ◽  
Coxa Vara ◽  
Single Center ◽  
The Third ◽  
Single Center Experience ◽  
Southern Turkey

Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome, caused by biallelic pathogenic mutations in the <i>PRG4</i> gene, is characterized by early-onset camptodactyly, noninflammatory arthropathy, coxa vara deformity, and rarely, pericardial effusion. Herein, we report 3 patients with CACP syndrome from 2 unrelated families. All patients are female, born to consanguineous parents, and had camptodactyly since the first years of their lives. Two patients had a prior diagnosis of juvenile idiopathic arthritis. Hip changes were present in 2 patients, and 2 of 3 patients had undergone surgery for camptodactyly. Routine echocardiographic evaluations were normal during the 2-year follow-up. This paper represents the third study including CACP patients from Turkey. Clinically, all 3 patients resembled juvenile idiopathic arthritis cases and received unnecessary medication. There is also an ongoing need for improving awareness of CACP and an effective treatment focusing on the lubrication of the joint space in CACP patients.

Temporomandibular Joint Involvement in Children with Juvenile Idiopathic Arthritis

2010 ◽  
Vol 38 (3) ◽  
pp. 510-515 ◽  
Author(s):  
ELVIRA CANNIZZARO ◽  
SILKE SCHROEDER ◽  
LUKAS M. MÜLLER ◽  
CHRISTIAN J. KELLENBERGER ◽  
ROTRAUD K. SAURENMANN
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Temporomandibular Joint ◽  
Upper Extremity ◽  
Age At Onset ◽  
Disease Onset ◽  
Joint Involvement ◽  
Hla B27 ◽  
Radiological Findings ◽  
Rheumatology Clinic ◽  
Younger Age

Objective.To determine the rate of temporomandibular joint (TMJ) involvement and find factors associated with TMJ arthritis in a single-center cohort of patients with juvenile idiopathic arthritis (JIA).Methods.Retrospective analysis of all patients with JIA visiting the rheumatology clinic between January 1, 2005, and December 31, 2006. Followup information was included until August 2008. A diagnosis of TMJ arthritis was based on clinical rheumatological and/or radiological findings.Results.After a mean followup time for JIA of 4.6 years (range 0.08–14.17), 86/223 patients (38.6%) had developed TMJ arthritis. The rate of TMJ involvement differed significantly among JIA subtypes (p = 0.0016), with 61% in extended oligoarticular, 52% in polyarticular rheumatoid factor (RF)-negative, 50% in psoriatic, 36% in systemic, 33% in polyarticular RF-positive, 33% in persistent oligoarticular, 30% in unclassified JIA, and 11% in enthesitis-related arthritis. The rate of TMJ involvement in our cohort was statistically significantly lower for patients who were HLA-B27-positive (p = 0.0002). In a multivariate analysis, the association of the following factors was confirmed: JIA subtype (p = 0.0001), a higher erythrocyte sedimentation rate (ESR) at diagnosis (p = 0.0038), involvement of joints of the upper extremity (p = 0.011), the absence of HLA-B27 (p = 0.023), and younger age at onset of JIA (p = 0.050).Conclusion.In our cohort of children with JIA, the overall rate of TMJ involvement was 38.6%. Patients with certain JIA subtypes, a higher ESR at disease onset, involvement of upper extremity joints, and younger age at diagnosis were more likely to develop TMJ arthritis. The presence of HLA-B27 seemed to be protective.

The Degree of Overjet and Anterior Traumatic Dental Injury in the Mixed Dentition: A Single-Center Experience

2019 ◽  
Vol 43 (5) ◽  
pp. 360-363 ◽  
Author(s):  
Monica Munro ◽  
Marc B Ackerman
Keyword(s):  
Chart Review ◽  
Young Patients ◽  
Retrospective Chart Review ◽  
Mixed Dentition ◽  
Single Center ◽  
Dental Injury ◽  
Single Center Experience ◽  
Single Center Study ◽  
Review Study ◽  
Center Study

Objective. The objective of this retrospective chart review study was twofold. The first was to determine whether there is a correlation between the degree of overjet and the type of anterior traumatic dental injury (ATDI) in the mixed dentition. The second was to assess whether the decision to not treat young patients with prominent upper front teeth for trauma prevention resulted in a greater number of ATDI's in patients of record from a single-center. Study Design. The authors conducted a retrospective chart review of patients presenting to the Boston Children's Hospital (BCH) Emergency Department with an ATDI in the mixed dentition between October 2011 and March 2016. Results. Patients with an overjet less than or equal to 4 millimeters experienced all types of ATDI with greater frequency than those patients with an overjet greater than 4 mm. Conclusions. Our experience at BCH described in this study has led us to believe that a patient's risk of suffering an ATDI has more to do with the type of activities they participate in rather than the degree of their overjet.

Safety of subcutaneous daratumumab in the treatment of plasma-cell disorders: A single-center experience.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20007-e20007
Author(s):  
Jung Kye ◽  
Magdalena Seyer ◽  
Samit Patel ◽  
Eun-Jeong Kim ◽  
Rhonda Hewitt ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Outpatient Setting ◽  
Single Center ◽  
Treatment Area ◽  
Single Center Experience ◽  
Frequent Use ◽  
Single Center Study ◽  
Plasma Cell Disorders ◽  
Delayed Reactions ◽  
Group 2

e20007 Background: Daratumumab (Dara) is a CD38-directed monoclonal antibody approved for the treatment of patients with multiple myeloma (MM) and light-chain amyloidosis (AL). Infusion-related reactions (IRRs) have been reported in 28-56% of individuals receiving the conventional intravenous (IV) formulation, necessitating slow infusions and frequent use of rescue medications to mitigate complications. Recently subcutaneous (SC) Dara received approval in MM, and randomized data suggests a lower rate of IRRs compared to IV Dara. Guidelines regarding post-injection monitoring with SC Dara are not well established. This retrospective study aims to evaluate the safety of SC Dara in patients with MM and AL, and to suggest guidelines for monitoring following SC Dara administration. Methods: This single-center retrospective study included patients treated with MM or AL receiving SC Dara between June 2020 and December 2020. The primary outcome of the study was incidence of IRRs. Secondary outcomes include timing and severity of IRRs based on CTCAE version 4.0. Results: A total of 82 patients received SC Dara during the study period. Of these 82, forty-nine (60%) had previously received Dara (Dara-exposed), and 33 patients (40%) were Dara-naïve. Eight of the 82 patients (9.8%) experienced an IRR. All were grade 1 (n=5, 63%) or grade 2 (n=3, 38%) in severity. Seven patients in the Dara-naïve group experienced an IRR (21%), and one patient in the Dara-exposed group (2%) experienced injection-site erythema with the second SC dose after transitioning from IV. Three patients experienced reactions immediately after SC Dara administration, and four patients experienced delayed reactions >4 hours after SC Dara administration (median 11.9 hours; range 5-24). Among those with delayed reactions, three experienced reactions after being discharged from the treatment area but symptoms resolved without any intervention. Conclusions: In this single-center study of patients receiving SC Dara, IRRs occurred in about 10% of patients, and were more likely with a patient’s first dose of SC Dara. All reactions were mild to moderate in severity and could be managed in the outpatient setting. We suggest that Dara-naïve patients receiving their 1st SC Dara dose be monitored for one hour after SC Dara administration. Monitoring does not appear necessary for patients transitioning from IV to SC Dara or receiving subsequent doses of SC Dara. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document